In this on-demand Tweetorial video from BREAST CANCER CONNECT, esteemed expert Dr Aditya Bardia presents a patient with ER+/HER2-low metastatic breast cancer, exploring the entire diagnostic and treatment process.

 

This is the second Tweetorial in a series on breast cancer management. Catch up on the first video to hear Dr Paolo Tarantino present a patient case with ER+/HER2- de novo metastatic breast cancer. 

 

Clinical Takeaways

  • Elacestrant improves PFS vs SOC in patients with ESR1m, irrespective of PIK3CAm or HER2-low status

  • Hyperglycemia is a target side effect of the PIK3CA inhibitors and needs to be monitored closely

  • T-DXd can be considered for patients with HER2-low mBC after ≥1 line of ChT

  • Recognise the efficacy and safety profiles of SERDs for patients with advanced or metastatic BC, and understand their place in the treatment landscape for patients with BC
  • Implement optimization of treatment selection, and make the appropriate sequencing decisions
  • Be able to identify and manage adverse events

Dr. Bardia is an internationally renowned breast oncologist known for his pioneering clinical and translational research in the field of cancer therapeutics, particularly antibody drug conjugates. Dr. Bardia led the development of sacituzumab govitecan, the first ADC approved for patients with metastatic triple negative breast cancer, as well as other including trastuzumab deruxtecan and datapotamab deruxtecan. Dr. Bardia also led the clinical development of elacestrant, the first oral SERD approved for patients with metastatic HR+ positive breast cancer. In translational collaboration with various labs, identified role of ESR1 mutations in mediating endocrine resistance, RB1 mutations in mediating CDK 4/6i resistance and TOP1 mutations in mediating ADC resistance. Besides cutting-edge research, Dr. Bardia is highly regarded among peers as an excellent mentor and strong advocate for academic trainees and junior faculty members. Dr. Bardia has received several awards including outstanding award for research excellence at Mayo Clinic, Young Investigator Award from ASCO, Distinguished researcher award from MASCO, and Douglas Family Foundation prize for excellence in oncology research.

Dr Aditya Bardia has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Consultant/Advisory board: Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics/Gilead, Sanofi, Daiichi Pharma/Astra Zeneca, Eli Lilly, Mersana. Contracted Research/Grant (to institution): Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics/Gilead, Daiichi Pharma/Astra Zeneca, Eli Lilly.

Programme summary
  • clock Duration 11 MIN
  • clock Language(s) flag
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Menarini Stemline Oncology.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Menarini Stemline Oncology.
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology, AstraZeneca and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Other programmes of interest

podcast Podcast
Oncology 
HR+/HER2- metastatic breast cancer: Best practices in molecular testing and targeted therapy

Optimising precision medicine for improved patient outcomes

Experts
Dr Roberto Salgado, Assoc. Clinical Professor Rena Callahan
Endorsed by
ICAN international cancer advocacy network ISLB Exon20group
Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Mar 2025

Educational programme supported by an Independent Educational Grant from Thermo Fisher Scientific.
conference-update Conference update
Oncology 
Current and future treatment strategies for patients with ER+/HER2- early breast cancer

A closer look at the evolving treatment landscape

Experts
Prof. Michael Gnant, Prof. Giuseppe Curigliano
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Mar 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
podcast Podcast
Oncology 
ER+ metastatic breast cancer: Key insights on elacestrant from the latest EMERALD subgroup analyses

Experts' insights on treatment strategies in ER+ metastatic breast cancer settings

Experts
Dr Aditya Bardia, Dr Virginia Kaklamani
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Mar 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
video Video
Oncology 
LEAP-012 publication snapshot

Expert insights on multimodal treatment for intermediate hepatocellular carcinoma (HCC)

Experts
Prof. Arndt Vogel
Endorsed by
DiCE Global Liver Institute Blue Faery plus
ELPA
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Mar 2025

This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this programme.
animated-video Animated Video
Oncology 
BRAF V600E mutated NSCLC: The evolving treatment landscape

Expert insights into personalised treatment strategies in BRAF-mutated NSCLC

Experts
Prof. Amanda Tufman
Endorsed by
BRAF Bombers ICAN international cancer advocacy network Biomarker Collaborative
  • clock MIN
  • calendar Mar 2025

This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
eks
Experts Knowledge Share Video
Oncology 
HER2 testing: The evolving role of immunohistochemistry (IHC)

Best practices and interpretation of results in lung and ovarian cancer 

Experts
Prof. Fernando López-Ríos, MD, PhD, Prof. Christian Rolfo, Prof. Charlie Gourley
Endorsed by
Exon20group ICAN international cancer advocacy network Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 77 MIN
  • calendar Mar 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca.